

# CITATION REPORT

List of articles citing

**Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources.**

**DOI: 10.1016/j.lanepe.2021.100266**

**Lancet Regional Health - Europe, The, 2022, 13, 100266.**

**Source:** <https://exaly.com/paper-pdf/123097763/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
22	Arid5a mediates an IL-17-dependent pathway that drives autoimmunity but not antifungal host defense.		
21	Candidiasis with interleukin-17 inhibitors. <i>Reactions Weekly</i> , <b>2021</b> , 1886, 8-8	0	
20	The Treatment with Interleukin 17 Inhibitors and Immune-Mediated Inflammatory Diseases. <i>Current Issues in Molecular Biology</i> , <b>2022</b> , 44, 1851-1866	2.9	0
19	Radiation Exposure Perturbs IL-17RA-Mediated Immunity Leading to Changes in Neutrophil Responses That Increase Susceptibility to Oropharyngeal Candidiasis. <i>Journal of Fungi (Basel, Switzerland)</i> , <b>2022</b> , 8, 495	5.6	0
18	Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors □ brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry. <i>Journal of Dermatological Treatment</i> , 1-11	2.8	0
17	Immunological effects of anti-IL-17/12/23 therapy in patients with psoriasis complicated by Candida infections. <i>Journal of Investigative Dermatology</i> , <b>2022</b> ,	4.3	1
16	Comorbidity in Adult Psoriasis: Considerations for the Clinician. <i>Psoriasis: Targets and Therapy</i> , Volume 12, 139-150	2.4	0
15	Exposure of Keratinocytes to Candida Albicans in the Context of Atopic Milieu Induces Changes in the Surface Glycosylation Pattern of Small Extracellular Vesicles to Enhance Their Propensity to Interact With Inhibitory Siglec Receptors. <i>Frontiers in Immunology</i> , 13,	8.4	0
14	Review and Practical Guidance on Managing Fungal Infections in Patients With Psoriasis Receiving Anti-IL-17 Therapies. <i>Journal of Cutaneous Medicine and Surgery</i> , 120347542211111	1.6	
13	IL-17 and IL-17-producing cells in protection versus pathology. <i>Nature Reviews Immunology</i> ,	36.5	8
12	A Fun-Guide to Innate Immune Responses to Fungal Infections. <b>2022</b> , 8, 805		0
11	Drug safety evaluation of ixekizumab for psoriasis: a review of the current knowledge. <b>2022</b> , 21, 1249-1257		0
10	A Review of the Safety of Interleukin-17A Inhibitor Secukinumab. <b>2022</b> , 15, 1365		0
9	Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis. <b>2022</b> , 23, 13913		1
8	Interleukin-12 and -23 Targeted Agents. <b>2022</b> , 199-217		0
7	Immune responses to human fungal pathogens and therapeutic prospects.		0
6	Arid5a Mediates an IL-17-Dependent Pathway That Drives Autoimmunity but Not Antifungal Host Defense. <b>2022</b> , 209, 1138-1145		0

- 5 English version of Japanese guidance for use of biologics for psoriasis (the 2022 version). ○
- 4 Adverse reactions of PDE5 inhibitors: An analysis of the World Health Organization pharmacovigilance database. ○
- 3 Saliva interleukin-17 levels are decreased in patients with severe oral candidiasis. ○
- 2 Amphoteric Mannan as an Immune Response Modifier. New Model Immunobiologically Active Candida albicans Mannan-Based Formula. 1-24 ○
- 1 Biologic Therapies in HIV/AIDS Patients with Inflammatory Diseases: A Systematic Review of the Literature. ○